FindTrial
Sign In

The effect and the safety study of the injection of nalmefene hydrochloride injection on the prevention of the sufentanil-induced cough during the induction period of general anesthesia

The effect and the safety study of the injection of nalmefene hydrochloride injection on the prevention of the sufentanil-induced cough during the induction period of general anesthesia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014683
Enrollment
Unknown
Registered
2018-01-29
Start date
2018-02-01
Completion date
Unknown
Last updated
2018-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The sufentanil-induced cough

Interventions

Group 1:5 ml saline
Group 2:1mg/kg lidocaine
Group 3:0.1ug/kg nalmefene
Group 4:0.2ug/kg nalmefene

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 60 Years

Inclusion criteria

Inclusion criteria: Aged <60 years; ASA I-II; Elective surgery under general anesthesia

Exclusion criteria

Exclusion criteria: 1) Patients with a history of hepatic or renal insufficiency, severe neurological or cardiovascular disease; 2) Patients allergic tonalmefene , lidocaine and other drugs; 3) Patients with psychologial disease or cognitive disorder, can't obey the study program, can't communicate well; 4) Patients refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Anesthesia depth influence;VAS for pain;—

Countries

China

Contacts

Public ContactXu Pingbo

Fudan University Shanghai Cancer Center

xupingboshanghai@163.com+86 18017312996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026